Kantarjian H, et al. "Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia". The New England Journal of Medicine. 2010. 362(24):2260-70.
Among patients with chronic-phase CML, does front-line therapy with dasatinib induce more rapid complete cytogenetic responses compared to the standard of care imatinib?
Among patients with chronic-phase CML, front-line dasatinib induces more complete cytogenetic responses at 12 months compared to imatinib.
IRIS (2003) was the first randomized trial to demonstrate the benefit of the tyrosine kinase inhibitor (TKI) imatinib over conventional therapy for patients with chronic-phase chronic myeloid leukemia (CML). Subsequently, several second-generation TKIs have been developed including dasatinib, nilotinib, and bosutinib, which may induce a more rapid response compared to imatinib.
This page was last modified on 18 October 2016, at 22:47.